NovoCure has obtained CE mark certification for its NovoTTF-100L system, a device that uses electrical fields to assist in the treatment of a rare form of cancer.

The noninvasive system is used alongside the chemotherapy drug pemetrexed and platinum-based chemotherapy for unresectable, locally advanced or metastatic malignant plural mesothelioma (MPM), a rare cancer linked to asbestos exposure.

The device uses tumor-treating electric fields to disrupt cell division, but the fields do not stimulate or heat tissue, so they cause minimal damage to healthy cells, NovoCure said.